The history of the patent law in India spans over 170 years, evolving from the colonial era where British commercial interests were the goal to a modern framework that tries to balance innovation and public good, progress and national development. These developments reflect India’s broader transition from colonial dependency to a self-reliant economy and, later, full integration into the global intellectual property regime under the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Today, the patent system in India serves as a cornerstone for fostering scientific research and development, attracting foreign investment, and ensuring affordable access to essential technologies, particularly in the field of healthcare.
The foundations of the patent system in India were laid during British rule. The first legislation, Act VI of 1856, granted exclusive privileges for new inventions based on the British Patent Law of 1852, offering a 14-year term for novel manufactures. The said Act lacked and was therefore repealed in 1857. It was then replaced by Act XV of 1859, which refined the system by terming monopolies as “exclusive privileges” and extending the priority period to 12 months. Subsequently laws were enacted which included the Patterns and Designs Protection Act (Act XIII of 1872) and the Protection of Inventions Act (1883). These laws were consolidated in 1888 and ultimately replaced by the comprehensive Indian Patents and Designs Act of 1911. This Act introduced formal requirements for novelty, utility, and inventive step, along with opposition and revocation procedures. However, it heavily favoured foreign and British applicants, restricting local innovation in an agrarian economy and limiting pharmaceutical product patents to protect imperial trade interests.
After India achieved independence, the shortcomings of the colonial patent system were recognized, and measures were taken to rectify it. Two expert committees: the Bakshi Tek Chand Committee (1949) and the Justice N. Rajagopala Ayyangar Committee (1957) criticised the 1911 Act for failing to stimulate indigenous invention or secure public benefits. Their observations and recommendations shaped the Patents Act, 1970, which came into force on 1 January 1972.
The new Act brought about a revolutionary shift: only process patents were allowed for food, drugs, chemicals, and medicines, enabling reverse engineering and generic production. This policy deliberately shortened patent terms for these sectors (five to seven years initially) while maintaining 14 years for inventions in other domains. Compulsory licensing under Section 84 was introduced to address non-working of patents or exorbitant pricing. The Act prioritised self-reliance, industrial growth, and affordable medicines, which acted as an impetus to the rise of India’s generic pharmaceutical industry. It transformed India into the “pharmacy of the world” while curbing foreign monopolies.
In 1995, India joined the WTO which brought the patent system in alignment TRIPS, which mandated product patents and a uniform 20-year term. A 10-year transition period was granted for developing countries. The Patents (Amendment) Act, 1999 introduced the “mailbox” system under Section 5 for deferred pharmaceutical product applications and Exclusive Marketing Rights (EMR) as interim protection. The 2002 Amendment extended the general patent term to 20 years, redefined “invention” to include inventive step, allowed deferred examination, made microorganisms patentable, and incorporated Bolar provisions for regulatory testing. The exhaustive Patents (Amendment) Act, 2005 which was effective retrospectively from 1 January 2005 deleted Section 5, opened the mailbox, and granted full product patents across all fields, including pharmaceuticals. Crucially, Section 3(d) was added to prevent “evergreening” by requiring enhanced therapeutic efficacy for minor modifications of known substances. Section 3(p) excluded traditional knowledge, while the Traditional Knowledge Digital Library was developed later to assist the examiners in this direction.
In its current form, the Patents Act, 1970 (as amended) is administered by the Indian Patent Office under the Controller General of Patents, Designs and Trade Marks. India has acceded to the Paris Convention, Patent Cooperation Treaty (PCT), and Budapest Treaty. The system now encourages research and development, biotechnology patents, and foreign direct investment while retaining flexibilities like compulsory licensing. Landmark cases such as Novartis v. Union of India (2013) have upheld Section 3(d), which has been crucial in ensuring cheap and affordable drugs.
The evolution of India’s patent system demonstrates pragmatic adaptation: from colonial exploitation to socialist self-reliance, and finally to TRIPS-compliant globalisation with strong public-interest safeguards. There are many challenges r such as application backlogs, enforcement delays, and balancing monopoly rights with healthcare equity but the Indian patent system has been successful in encouraging innovation, positioned India as a global generics leader, and ensured that intellectual property serves both economic progress and welfare of the nation. As India aspires to become a developed nation by 2047, its patent history continues to guide this delicate equilibrium.